Sign In
Buy FBIO
$2.61
-0.0400 (-1.51%)
At Close: Jun 03, 2026
NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or mon
Fortress Biotech Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
08:30pm, Monday, 10'th Aug 2020
Product revenue for the first six months of 2020 increased 50% year-over-year to $21.4 million Agreement executed with Columbia University to develop novel oligonucleotide platform for the treatment
Qiagen, Pandion See Activist Actions
12:15am, Saturday, 08'th Aug 2020
Davidson Kempner Capital Management reported an 8% interest the Netherlands-based molecular testing firm Qiagen. Boxer Capital now owns 2,107,513 shares of newly public clinical-stage biopharmaceutica
LD Micro-Announces Preliminary List of Presenters for the LD 500.
07:34pm, Wednesday, 05'th Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 5, 2020 / LD Micro today announced the initial list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively onlin
49 Public Companies to Present at the SNN Network Virtual Conference on August 3-6, 2020
12:00pm, Monday, 03'rd Aug 2020
LOS ANGELES, CA / ACCESSWIRE / August 3, 2020 / The SNN Network Virtual Conference will take place on August 3rd \\- 6th, 2020, where 49 SmallCap, MicroCap and NanoCap public companies will be present
Rolling submission of New Drug Application to the FDA for CUTX-101 on track to begin in the fourth quarter of 2020NEW YORK, July 31, 2020 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“
Cyprium Therapeutics, a Fortress partner company, is developing CUTX-101 for Menkes disease A rolling submission of a New Drug Application to the FDA is expected to begin in the fourth quarter of 202
Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results
12:30pm, Tuesday, 21'st Jul 2020
NEW YORK, July 21, 2020 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.
Fortress Biotech, Inc.'s (NASDAQ:FBIO) Path To Profitability
05:43pm, Monday, 20'th Jul 2020
Fortress Biotech, Inc.'s (NASDAQ:FBIO): Fortress Biotech, Inc. develops and commercializes pharmaceutical and...
Mustang Bio (NASDAQ:MBIO) Downgraded by Zacks Investment Research
06:36pm, Wednesday, 15'th Jul 2020
Mustang Bio (NASDAQ:MBIO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com report
$11.59 Million in Sales Expected for Fortress Biotech (NASDAQ:FBIO) This Quarter
02:00am, Wednesday, 15'th Jul 2020
Analysts predict that Fortress Biotech (NASDAQ:FBIO) will report $11.59 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Fortress Biotech’s ear
How R&D Expenses Can Help You Pick Outperforming Stocks
12:13pm, Thursday, 02'nd Jul 2020
A simple two-rule screen can help you pick R&D-intensive stocks primed to outperform. The differences between R&D expenditures and capital expenditures vary bet
FORTRESS REIT LIMITED – Posting of circular and notice of general meetings - SENS
02:17pm, Tuesday, 30'th Jun 2020
Sens announcement for FORTRESS REIT LIMITED – Posting of circular and notice of general meetings - SENS
FORTRESS REIT LIMITED – Update regarding disposal of non-core assets - SENS
12:42pm, Monday, 29'th Jun 2020
Sens announcement for FORTRESS REIT LIMITED – Update regarding disposal of non-core assets - SENS
Fortress Biotech Added to Russell 3000® Index
12:30pm, Monday, 29'th Jun 2020
Annual Russell indexes’ reconstitution captures the 4,000 largest U.S. stocks as of May 8, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which re
